InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.78
(
0.01%
)
US TECH 100
19,269.20
(
0.05%
)
Dow Jones
39,136.04
(
0.00%
)
Brent Oil
84.42
(
-0.69%
)
Bitcoin
63,693.57
(
-1.74%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jaybe

Send PM Follow Ignore
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

jaybe

Re: None

Friday, 06/28/2013 10:45:03 PM

Friday, June 28, 2013 10:45:03 PM

Post# of 80490
New Paradigm for Switching TKIs in CML...

CML KOL's set the table for switching TKI therapy in recent study from June 26, 2013.

"BCR-ABL1 transcript levels =10% at 3 months, <1% at 6 months, and =0.1% from 12 months onward, define optimal response, while >10% at 6 months and >1% from 12 months onward define failure, mandating a change of treatment."

Note EPIC trial has secondary outcome measure of rate of BCR-ABL1 transcript levels <10% at 3 months, which could be reached by ASH in December.


http://www.ncbi.nlm.nih.gov/pubmed/23803709




Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up